The Asia Pacific Oral Antiviral Market would witness market growth of 3.2% CAGR during the forecast period (2023-2029).
The market is expanding due to several causes, including an expanding patient population, an increase in viral disease cases, and rising disease awareness. In addition, the market is expanding due to growing awareness of the need for early disease detection, rising healthcare expenditures in emerging nations, rising government and industry investment, and other factors. The market expansion is anticipated to be fueled by regulatory approvals for special drug designation for treatment and a robust R&D pipeline.
Many people with an uncomplicated case of influenza take over-the-counter medications, rest, and drink lots of water to ease their symptoms. Antiviral medications, available by prescription, can shorten recovery from symptoms. Some can also be used in specific circumstances to lessen the likelihood that those exposed to the influenza virus would become ill. The best results from antiviral medications may be seen in people who begin treatment within 48 hours of the onset of symptoms. Therefore, prompt medical examination is crucial for the early treatment of influenza.
The economic growth of this region is influenced by the development of the healthcare infrastructure, the expansion of government initiatives to boost the uptake of treatments and the regional expansion of significant corporations in Asian nations. The rising prevalence of herpes in developing countries such as China and India is also expected to contribute to development. Since there are numerous regional companies, the market is dispersed, which increases the rate at which oral antiviral medications are used for treating herpes. Asia-Pacific offers lucrative potential for key players operating in the market due to improvements in sector infrastructure, a rise in spending power, and the well-established presence of market players in the region.
The China market dominated the Asia Pacific Oral Antiviral Market by Country in 2022 thereby, achieving a market value of $2,989.9 million by 2029. The Japan market is exhibiting a CAGR of 2.6% during (2023 - 2029). Additionally, The India market would experience a CAGR of 3.8% during (2023 - 2029).
Based on Indication, the market is segmented into Human Immunodeficiency Virus (HIV), Hepatitis, Influenza and Others. Based on Drug Class, the market is segmented into Reverse Transcriptase Inhibitors, Protease Inhibitors and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Oral Antiviral Market is Projected to reach USD 41.2 Billion by 2029, at a CAGR of 2.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Gilead Sciences, Inc., Viatris, Inc. (Mylan N.V.), AbbVie, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceutical Industries Ltd., and Amneal Pharmaceuticals, Inc.
By Indication
By Drug Class
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
